TII
12.8.2024 13:47:19 CEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has released a new large language model in its Falcon series, the Falcon Mamba 7B. The new model is the no. 1 globally performing open source State Space Language Model (SSLM) in the world, as independently verified by Hugging Face.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240812019509/en/
UAE’s Technology Innovation Institute Revolutionizes AI Language Models With New Architecture (Photo: AETOSWire)
As the first SSLM for Falcon, it departs from prior Falcon models which all use a transformer-based architecture. This new Falcon Mamba 7B model is yet another example of the pioneering research the institute is conducting and the breakthrough tools and products it makes available to the community in an open source format.
H.E. Faisal Al Bannai, Secretary General of ATRC and Adviser to the UAE President for Strategic Research and Advanced Technology Affairs, said: “The Falcon Mamba 7B marks TII’s fourth consecutive top-ranked AI model, reinforcing Abu Dhabi as a global hub for AI research and development. This achievement highlights the UAE’s unwavering commitment to innovation.”
For transformer architecture models, Falcon Mamba 7B outperforms Meta’s Llama 3.1 8B, Llama 3 8B, and Mistral’s 7B on the newly introduced benchmarks from HuggingFace. Meanwhile for the other SSLMs, Falcon Mamba 7B beats all other open source models in the old benchmarks and it will be the be first model on HuggingFace’s new tougher benchmark leaderboard.
Dr. Najwa Aaraj, Chief Executive of TII, said: “The Technology Innovation Institute continues to push the boundaries of technology with its Falcon series of AI models. The Falcon Mamba 7B represents true pioneering work and paves the way for future AI innovations that will enhance human capabilities and improve lives.”
State Space models are extremely performant at understanding complex situations that evolve over time, such as a whole book. This is because SSLMs do not require additional memory to digest such large bits of information.
Transformer based models, on the other hand, are very efficient at remembering and using information they have processed earlier in a sequence. This makes them very good at tasks like content generation, however, because they compare every word with every other word, this requires significant computational power.
SSLMs can find applications in various fields such as estimation, forecasting, and control tasks. Similar to the transformer architecture models, they also excel in Natural Language Processing tasks and can be applied to machine translation, text summarization, computer vision, and audio processing.
Dr. Hakim Hacid, Acting Chief Researcher of the TII’s AI Cross-Center Unit, said: “As we introduce the Falcon Mamba 7B, I’m proud of the collaborative ecosystem of TII that nurtured its development. This release represents a significant stride forward, inspiring fresh perspectives and further fueling the quest for intelligent systems. At TII, we’re pushing the boundaries of both SSLM and transformer models to spark further innovation in generative AI.”
Falcon LLMs have been downloaded over 45 million times, proving the outstanding success of the models. Falcon Mamba 7B will be released under TII Falcon License 2.0, the permissive Apache 2.0-based software license which includes an acceptable use policy that promotes the responsible use of AI. More information on the new model can be found at FalconLLM.TII.ae.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812019509/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
